These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38962456)

  • 1. A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.
    Yamano T; Hamakawa M; Akaike Y; Ishida T
    Clin Case Rep; 2024 Jul; 12(7):e9153. PubMed ID: 38962456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
    Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
    Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.
    Liang I; Chu G; Zielinski R
    Case Rep Oncol; 2023; 16(1):182-187. PubMed ID: 37013108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
    Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
    Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
    Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
    World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
    Jiang JJ; Li YQ; Gu YY
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):47-52. PubMed ID: 35000305
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.
    Matsumoto S; Watanabe K; Kobayashi N; Irie K; Yamanaka S; Kaneko T
    Respirol Case Rep; 2020 Jul; 8(5):e00560. PubMed ID: 32284868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.
    Ooi R; Tobino K; Sakabe M; Kawabata T; Hiramatsu Y; Sueyasu T; Yoshimine K
    Respir Med Case Rep; 2020; 31():101197. PubMed ID: 32944497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
    Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
    Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments.
    Okamoto K; Hijioka S; Nagashio Y; Okada M; Ohba A; Maruki Y; Kondo S; Morizane C; Ueno H; Okusaka T
    Jpn J Clin Oncol; 2024 Aug; 54(8):887-894. PubMed ID: 38715325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report.
    Hashimoto T; Takahashi K; Ito K; Iwade K; Torii A; Sugihara M; Kondo H; Hara T
    Int Cancer Conf J; 2024 Jul; 13(3):218-222. PubMed ID: 38962041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
    Kocheise L; Piseddu I; Vonderlin J; Tjwa ET; Buescher G; Meunier L; Goeggelmann P; Fianchi F; Dumortier J; Riveiro Barciela M; Gevers TJG; Terziroli Beretta-Piccoli B; Londoño MC; Frankova S; Roesner T; Joerg V; Schmidt C; Glaser F; Sutter JP; Fründt TW; Lohse AW; Huber S; von Felden J; Sebode M; Schulze K
    Front Immunol; 2023; 14():1326078. PubMed ID: 38268921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
    Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
    Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.